NeuroSense Therapeutics Ltd.
NRSNHealthcare|Biotechnology|IL
$1.68
+0.28 (+20.43%)
Cash / Share
$0.18
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05357950 A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS | Amyotrophic Lateral Sclerosis, ALS | P2 | Completed | 69 | RCT, Double-blind | PrimeC, Placebo |
| NCT06185543 A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease. | Alzheimer Disease | P2 | Terminated | 8 | RCT, Double-blind | PrimeC, Placebo |
| NCT04165850 Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS | Amyotrophic Lateral Sclerosis, ALS | P2 | Completed | 16 | Open-label | Fixed dose combination Ciprofloxacin/Celecoxib |
| NCT05436678 A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject | Pharmacokinetics | P1 | Completed | 19 | RCT, Open-label | PrimeC 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg |
| NCT04090684 Ciprofloxacin/Celecoxib Combination in Patients With ALS | ALS (Amyotrophic Lateral Sclerosis) | P1 | Completed | 10 | Open-label | Fixed dose combination Ciprofloxacin/Celecoxib |
| NCT05232461 A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects | Pharmacokinetics | P1 | Completed | 12 | RCT, Open-label | PrimeC-ER 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg |